Lannett adds Silarx's liquid manufacturing to its operations

Philadelphia-based generic maker Lannett says it has beefed up its manufacturing, and its generic portfolio, with the acquisition of Silarx for an undisclosed amount. Silarx specializes in liquid products, both generic prescriptions and over-the-counter, which it manufactures at its 110,000-square-foot facility in Carmel, NY. "Upon closing, the acquisition will add a high quality, talented research team and manufacturing capacity," Lannett CEO Arthur Bedrosian said in a statement. Release

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.